MULTIPLE MYELOMA (15 trials)

1. TRIlogy-5 – A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1-3 prior lines of therapy

2. DREAMM-15 – A Phase 2, multicenter, open-label, non-randomized study to evaluate the safety and efficacy of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma

3. DREAMM-8 (GSK207499) – A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (B-Pd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in participants with relapsed/refractory multiple myeloma

4. TAK-339-3001 – A Phase 3 Study in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA Therapy

5. R5458-ONC-2246 (Linvoseltamab) – An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib Versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma

6. MagnetisMM-05 (C1071005) – An open-label, 3-arm, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of Elranatamab monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 1 prior line of therapy including Lenalidomide and a proteasome inhibitor

7. MagnetisMM-06 (C1071006) – An open-label, 2-arm, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of Elranatamab + Daratumumab + Lenalidomide versus Daratumumab + Lenalidomide + Dexamethasone in transplant-ineligible participants with newly-diagnosed multiple myeloma

8. MagnetisMM-07 (C1071007) – A randomized, 2-arm, Phase 3 study of Elranatamab versus Lenalidomide in patients with newly diagnosed Multiple Myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation

9. MagnetisMM-032 – A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab/Pomalidomide/Dexamethasone (EPd) or Pomalidomide/Bortezomib/Dexamethasone (PVd) or Carfilzomib/Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy

10. EAE-115 – A Phase 2 study of Isatuximab in combination with Pomalidomide and Dexamethasone in Multiple Myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor

11. EAE-116 – A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by Isatuximab and Lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment

12. SELECT (20180117) – KPd Study – An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone

13. Gammagard Liquid (Takeda) – A Phase 3, multicenter, randomized, controlled, open-label, sequential-cohort study to investigate the efficacy, safety, and tolerability of intravenous Gammagard Liquid (immune globulin infusion, 10%) for primary infection prophylaxis versus secondary infection prophylaxis in adult participants with multiple myeloma receiving BCMA × CD3 bispecific antibody therapy

14. REALiTEC/REALiTAL – A Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials

15. Carfilzomib Real-World Study – Real-world evidence of the use of a carfilzomib triplet including an anti-CD38 antibody in patients with multiple myeloma who have received at least one prior therapy

ACUTE MYELOID LEUKEMIA (6 trials)

16. KO-MEN-017 (Ziftomenib) – Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

17. 75276617AML3001 – cAMeLot (Bleximenib) – A Study of Bleximenib in Combination with Venetoclax + Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations who are ineligible for intensive chemotherapy

18. Galinpepimut-S (SLSG18-301) – A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

19. SECURE – Real-world treatment patterns and clinical outcomes in unfit AML patients in Greece receiving first-line systemic therapy or best supportive care

20. SURVIVE – Prospective non-interventional study describing the effectiveness and safety of first-line treatment in AML patients ineligible for intensive chemotherapy in routine clinical practice in Greece

21. MURAL – A multi-country real-world study to explore treatment patterns, clinical outcomes, and healthcare resource utilization in patients with MDS/AML per ICC 2022 criteria

ACUTE LYMPHOBLASTIC LEUKEMIA (2 trials)

22. Golden Gate (20190360) – Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia with Safety Run-in

23. AUDAX (20240113) – A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults with Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia

MYELODYSPLASTIC SYNDROMES (3 trials)

24. TAK-226-3001 (Elritercept) – A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

25. P-SP420-THAL-01 – An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

26. MBG453 (Sabatolimab) – A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of Azacitidine with or without MBG453 for the treatment of patients with intermediate, high, or very high risk myelodysplastic syndrome (MDS) according to IPSS-R criteria, or with chronic myelomonocytic leukemia-2 (CMML-2)

MYELOFIBROSIS (7 trials)

27. KRT-232-115 (Navtemadlin) – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF That Have a Suboptimal Response to Ruxolitinib

28. BOREAS-2 (Navtemadlin) – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with PMF, Post-PV-MF, or Post-ET-MF Following a Suboptimal Response to Ruxolitinib

29. KRT-232-101 – A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

30. XPORT-MF-044 (Selinexor) – A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia

31. XPORT-MF-034 (Selinexor) – A Phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis

32. MANIFEST-2 (CPI-0610-04, Pelabresib) – A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naïve MF Patients

33. METER – A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed with Myelofibrosis through Chart Review

CHRONIC LYMPHOCYTIC LEUKEMIA (5 trials)

34. BELLWAVE-011 (Nemtabrutinib) – A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants with Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

35. PRO-SID / NGAM-12 (Panzyga) – A Double-Blind, Randomized, Placebo-Controlled, Prospective Phase 3 Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

36. MiraCLLe (D133FR00166) – A Greek non-interventional, prospective, 2-year cohort study to record first and second-line treatment strategies, outcomes, quality of life, and healthcare resource utilization in patients with Chronic Lymphocytic Leukemia in daily clinical practice in Greece

37. Concrete (P19-568) – Clinical outcomes of relapsed/refractory Chronic Lymphocytic Leukemia patients treated with Venetoclax in routine clinical settings in Greece

38. Respire (H19-476) – Retrospective analysis of clinical outcomes of relapsed/refractory Chronic Lymphocytic Leukemia patients treated with Venetoclax in Greece

LYMPHOMA (9 trials)

39. GOLSEEK-1 (CA073-1020) – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma

40. GOLSEEK-4 – A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator's Choice in Participants with Relapsed/Refractory Follicular Lymphoma

41. ARCHED / GLA 2022-1 – A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma

42. EXS73565-001 – A Phase 1, open-label, multicenter, dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of EXS73565 in participants with relapsed or refractory B-cell malignancies

43. EPCORE FL-1 (M20-638) – A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab in Combination with Rituximab and Lenalidomide (R²) compared to Rituximab and Lenalidomide (R²) alone in Subjects with Relapsed or Refractory Follicular Lymphoma

44. EPCORE DLBCL (M20-621) – A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

45. EpcoReal – A multinational, prospective observational study of epcoritamab in Non-Hodgkin Lymphoma including two cohorts: patients with (diffuse) large B-cell lymphoma receiving 2nd or later line therapy and patients with follicular lymphoma receiving 2nd or later line therapy

46. VEGA (MCL3004) – A Randomized, Controlled, Open-label, Multicenter, Phase 2/Phase 3 Study of Ibrutinib in Combination with Rituximab Versus Physician's Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma who are BTK inhibitor-naïve

47. PCYC-1143-CA – A Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

IMMUNE THROMBOCYTOPENIA (3 trials)

48. Budoprutug (TNT119) – A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug in Subjects with Immune Thrombocytopenia (ITP)

49. UCB ITP Study – A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IMP in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

50. myOpportunITy (TP0003, Rozanolixizumab) – A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (1 trial)

51. BO42162 (Crovalimab) – A Phase 3, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors

INFECTION PROPHYLAXIS (1 trial)

52. ASPER-III-19-1 (Inhaled Itraconazole) – A Phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety, and tolerability of Itraconazole dry powder for inhalation for the prevention of invasive mould disease in patients with Acute Leukaemia and Neutropenia